June 9, 2021

Join Our Discussion: Bridging the Gap Between R&D Innovation and Biomanufacturing

The stakes have never been higher for biomanufacturing. Its explosive growth over the past decade has created a massive need to constantly innovate to keep up with patient need and overseas competition.

Often, the industry is faced with a “gap” between innovation that occurs on university research campuses and the large-scale, private biomanufacturing sector. This gap can include several factors such as lack of funding, talent pipeline shortages, and infrastructure limits—all of which slow down innovation and speed-to-market. Join this panel discussion to hear from the foremost experts in this field and how they are addressing these challenges in their own organizations.

When: July 1st, 12pm PST/ 3pm ET


About our moderator:

Alicia Pandimos Maurer, AIA, LEED AP, Vice President and Laboratory Designer, CannonDesign

Alicia Pandimos Maurer is a laboratory designer whose 20+ years’ experience has spanned an array of specialty sciences such as genetics, gene and cell therapy, personalized medicine, microbiology, cell culture, and PCR and sequencing. From planning through construction administration and post-occupancy, Alicia has led both consultants and internal teams through all project phases. She considers herself a conduit for information to flow back and forth between the design and construction team and the owner and end-users. Passionate about sustainable lab design, Alicia is a thought-leader in this field, helping found the Colorado chapter of the International Institute for Sustainable Laboratories (I2SL) and currently sits on the San Diego board for I2SL.

About our panelists:

Rick Fultz, Sr. Vice President and Chief Business Officer, Biocom and Interim Executive Director, Biocom San Diego

Rick Fultz is Senior Vice President and Chief Business Officer of Biocom California. He is responsible for leading the organization’s membership, sponsorship, marketing and business systems efforts as well as partnering initiatives and overall business development. Recently he has taken on the role of Interim Executive Director for Biocom’s San Diego Office.

Bruce Levine, Ph.D., Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene-edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,300 patients in clinical trials since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 29 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 92. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award, serves as President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.

Derek Rae, ASHE, Senior Vice President/Principal, Leader of OAC’s Healthcare, Biomedical, and Life Science Market Sectors

Derek’s passionate spirit and diverse background have translated into cost-saving, sustainable, award-winning work for significant healthcare, life-science, and commercial clients. For over 25 years, Derek has worked as an owner’s representative and general contractor, leading successful project teams and expanding OAC’s services to the San Diego market. As an industry leader, Derek is involved in all aspects of construction programs, from master planning to final execution. He is best known for fostering long-term client relationships, employing risk avoidance strategies, and successfully managing contract negotiations. 

Gregory Theyel, Ph.D., Director, Biomedical Manufacturing Network

Gregory Theyel is the Director of the Biomedical Manufacturing Network, which assists companies with the commercialization of technology and maintains a global database and maps of biomedical companies. Gregory is a manufacturing engineer with over 20 years of experience helping companies with strategy, product and process design, production planning, and supply chain management. He has assisted over 500 companies as well as started and run his own companies. He has a doctorate from Clark University, has published more than 50 peer-reviewed articles, and has taught industrial engineering and management courses. Gregory was formerly a Senior Research Fellow, at the Institute for Manufacturing at the University of Cambridge, United Kingdom where he was Program Director for the High Value Production Program. His research is on the innovation and diffusion of manufacturing technology with a focus on production location and supply chain traceability.